Cadila Healthcare Limited engages in the research, development, production, marketing, and distribution of pharmaceutical products. Its product portfolio includes active pharmaceutical ingredients, veterinary, and human formulations. The company offers branded formulations in the therapeutic areas of neurological, neutraceutical, pain management, gastro intestinal, respiratory, anti-infective, biological, cardiovascular, female healthcare, dermatology, and others. It also provides consumer wellness products, such as Sugar Free, a low calorie sugar substitute; EverYuth, a range of skincare products; and Nutralite, a cholesterol free table spread. In addition, the company researches and develops a pipeline of 24 biologics comprising 20 biosimilars and 4 novel biological products; and new drugs in cardio-metabolic, inflammation, pain, and oncology therapeutic areas. Further, it provides animal healthcare products. Additionally, the company develops vaccines that are designed to address infectious diseases, including next-generation influenza, measles-mumps-rubella-varicella, typhoid, DPT-HiB, hepatitis-B, hepatitis-A, hepatitis-E, Japanese encephalitis, HPV, and combination vaccines. The company was founded in 1952 and is headquartered in Ahmedabad, India.
cadila healthcare ltd
(CDH:National Stock Exchange of India)
Satellite Cross Roads
Phone: 91 79 2686 8100
Fax: 91 79 2686 2365www.zyduscadila.com
|Cipla Ltd/India||709.05 INR||-2.00|
|Glenmark Pharmaceuticals Ltd||1,012 INR||+55.35|
|Piramal Enterprises Ltd||920.20 INR||+18.55|
|Torrent Pharmaceuticals Ltd||1,442 INR||+5.65|
|Wockhardt Ltd||1,564 INR||+77.55|
|View Industry Companies|
Sponsored Financial Commentaries
To contact CADILA HEALTHCARE LTD, please visit www.zyduscadila.com. Company data is provided by Capital IQ. Please use this form to report any data issues.